London, 27 June 2002
Doc. Ref: EMEA/CPMP/3065/02

PRESS RELEASE
European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products Meeting of 25 to 27 June 2002

No opinions on initial marketing authorisation applications were adopted at this meeting.

The CPMP finalised its Community-level review of **sibutramine** containing medicinal products (Reductil, Meridia, Reduxade, Sibutral and associated brand names). The re-assessment of the efficacy and safety of sibutramine was initiated following a request by Italy in March 2002. The Committee considers that the risk-benefit profile of sibutramine remains positive. The CPMP will continue to keep the product under regular review, including the follow-up to the clinical trial previously requested by the Committee in November 2000.

A more detailed CPMP meeting report will be made available next week, including details from the MRFG meeting of 27 May 2002.

--ENDS--

For further information, please contact:

Martin Harvey, EMEA press officer
Tel. (44-20) 74 18 84 27
E-mail: martin.harvey@emea.eu.int

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 09
E-mail: mail@emea.eu.int http://www.emea.eu.int